NUVB News and Press, Nuvation Bio Inc. Class A From 03/15/23

Initiated both dosing regimens of the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Dosing ongoing for Phase 1 monotherapy study of NUV-868 Nominated undisclosed Drug-Drug Conjugate (DDC) as first clinical candidate; expect to submit an IND by year end 202...

Baupost Group took new stakes in Altice USA ( NYSE: ATUS ), with a 3.88M shares, and in Herbalife Nutrition ( NYSE: HLF ), with 2.00M shares, during the quarter ended Dec. 31, 2022, according to its latest 13F filing. Overall, the firm run by Seth Klarman increased its bets on tec...

Summary David Abrams’ 13F portfolio value decreased this quarter from $3.47B to $2.80B. The number of positions decreased from 18 to 15. The Meta Platforms stake was increased substantially while decreasing TransDigm Group, Energy Transfer, Alphabet, Willis Towers Watson, and Tev...

Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of advanced solid tumors Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing dif...

Summary David Abrams’ 13F portfolio value decreased this quarter from $3.72B to $3.47B. The number of positions remained steady at 18. The Kinder Morgan stake was reduced substantially this quarter. The top three positions are Lithia Motors, Change Healthcare, and Ashbu...

Nuvation Bio press release ( NYSE: NUVB ): Q3 GAAP EPS of -$0.12 beats by $0.02 . Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $673.9M as of September 30, 2022. For further details see: Nuvat...

Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors Expect to initiate Phase 1b combination study of NUV-868 by the end of 2022 On track to nominate first clinical candidate from Drug-Drug Conjugate (DDC) platform by the end of 2022 ...

David Abrams’ 13F portfolio value decreased this quarter from $4.28B to $3.72B. The number of positions remained steady at 18. The portfolio was untouched this quarter. The top three positions are Lithia Motors, Change Healthcare, and Asbury Automotive. They add up to ~38% ...

Seth Klarman’s 13F portfolio value decreased from $9.30B to $6.77B this quarter. Baupost Group added Warner Bros. Discovery and Amazon while reducing Alphabet, Intel Corp., Nexstar Media, and Verint Systems. The portfolio continues to be heavily concentrated with the top th...

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N....